Recent Health Articles: Orphan Diseases Therapeutics in Oncology to 2018 - Strongly Diversified Developmental Pipelines Indicate Long-Term Growth Potential despite Moderate Scope of Current Late Stage Molecules

Orphan Diseases Therapeutics in Oncology to 2018 - Strongly Diversified Developmental Pipelines Indicate Long-Term Growth Potential despite Moderate Scope of Current Late Stage Molecules

NEW YORK, May 10, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

-Scope-of-Current-Late-Stage-Molecules.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy title='Orphan Diseases Therapeutics in Oncology to 2018 - Strongly Diversified Developmental Pipelines Indicate Long-Term Growth Potential despite Moderate Scope of Current Late Stage Molecules'>Orphan Diseases Therapeutics in Oncology to 2018 - Strongly Diversified Developmental Pipelines Indicate Long-Term Growth Potential despite Moderate Scope of Current Late Stage Molecules

http://www.reportlinker.com/p0850352/Orphan-Diseases-Therapeutics-in-Oncology-to-2018---Strongly-Diversified-Developmental-Pipelines-Indicate-Long-Term-Growth-Potential-despite-Moderate-

-Scope

-of-Current-Late-Stage-Molecules.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

Orphan Diseases Therapeutics in Oncology to 2018 - Strongly Diversified Developmental Pipelines Indicate Long-Term Growth Potential despite Moderate Scope of Current Late Stage Molecules

Summary GBI Research, the leading business intelligence provider, has released its latest research "Orphan Diseases Therapeutics in Oncology to 2018 - Strongly Diversified Developmental Pipelines Indicate Long-Term Growth Potential despite Moderate Scope of Current Late Stage Molecules", which provides insights into the Oncology orphan disease therapeutics market until 2018. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts. The report provides an in-depth analysis of pancreatic cancer, ovarian cancer, multiple myeloma, acute myeloid leukemia as well as Hodgkin lymphoma in the last seven years as well as throughout the forecast period until 2018. The report examines the global orphan diseases therapeutics in Oncology usage patterns. It includes the geographical distribution of pancreatic cancer, ovarian cancer, multiple myeloma, acute myeloid leukemia and Hodgkin lymphoma markets across the US, the top five European countries and in Japan. The report also includes insights into the orphan diseases therapeutics in Oncology Research and Development (R&D) product pipeline and explores the competitive landscape, including major players in the Oncology orphan disease therapeutics market. Finally, the report includes an analysis of Mergers and Acquisitions (M&A) as well as co-development and licensing deals that took place in the orphan diseases therapeutics in Oncology market in the last seven years.

GBI Research's analysis shows that the overall global Oncology orphan disease market is expected to grow at a significant compound annual growth rate (CAGR) of 3.3% from $4.9 billion 2010 to $6.4 billion in 2018 in the US, the top five European countries and Japan. This growth follows a higher CAGR of 7.4% between 2004 and 2010. Although the aggregate market revenues have been and are expected to grow consistently between 2004 and 2018, the individual therapeutic markets for the orphan cancer indications exhibit much more differentiated and diversified dynamics. The therapeutic market for pancreatic cancer is expected to decline substantially, but to recover towards the end of the forecast period. The ovarian cancer and multiple myeloma therapeutic markets are expected to grow at a very moderate CAGR over the forecast period due to important patent expiries in the multiple myeloma market. The acute myeloid leukemia and Hodgkin lymphoma therapeutic markets are expected to grow at significant and very high CAGRs in the forecast period, respectively. Similarly differentiated dynamics have been identified in the annual costs of therapy in these therapeutic markets.

Scope

- Data and analysis on the orphan diseases therapeutics in oncology market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain and Japan.- Annualized market data for the orphan diseases therapeutics in oncology market from 2004 to 2010, with forecasts to 2018.- Market data on the geographical landscape and therapeutic landscape, including market size, annual cost of therapy, sales volume and treatment usage patterns such as disease population, diagnosis population and prescription population.- Key drivers and restraints that have had a significant impact on the market.- The competitive landscape of the global market including top companies benchmarking. The key companies studied in this report are Celgene Corporation, Genentech, Inc, Amgen, Eli Lilly and Company, Takeda.- Key M&A activities, co-development and licensing agreements that took place between 2004 and 2011 in the orphan diseases therapeutics in oncology market.

Reasons to buy

- Align your product portfolio to the markets with high growth potential.- Build effective strategies to launch their pipeline products by identifying potential geographies.- Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.- Develop key strategic initiatives by studying the key strategies of top competitors.- Create a more tailored country strategy through the understanding of key drivers and barriers and market potential of each indication.- Develop market entry and market expansion strategies by identifying the geographic markets poised for strong growth.- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.1 Table of Contents1 Table of Contents 41.1 List of Tables 71.2 List of Figures 92 Orphan Diseases Therapeutics in Oncology - Introduction 112.1 Introduction 112.2 Introduction to Cancer Etiology 112.3 Drug Classes and their Mechanisms of Action in the Treatment of Cancer 122.4 GBI Research Report Guidance 143 Orphan Diseases Therapeutics in Oncology - Market Overview 153.1 Revenues 153.2 Annual Cost of Therapy 163.3 Treatment Usage Pattern 173.3.1 Diseased Population 183.3.2 Diagnosed Population 183.3.3 Prescription Population 184 Orphan Diseases Therapeutics in Oncology - Geographical Landscape 194.1 Introduction 194.2 The US 194.2.1 Sales Revenues 194.2.2 ACT 214.2.3 Treatment Usage Patterns 224.3 Top Five Countries of Europe 244.3.1 Sales Revenues 244.3.2 ACT 264.3.3 Treatment Usage Patterns 274.4 Japan 294.4.1 Sales Revenues 294.4.2 ACT 304.4.3 Treatment Usage Patterns 315 Orphan Diseases Therapeutics in Oncology - Therapeutic Landscape 335.1 Pancreatic Cancer Therapeutics Market 335.1.1 Introduction 335.1.2 Sales Revenues 345.1.3 ACT 365.1.4 Treatment Usage Patterns 375.1.5 Marketed Products 385.1.6 Drivers and Barriers in the Pancreatic Cancer Therapeutics Market 395.2 Ovarian Cancer Therapeutics Market 415.2.1 Introduction 415.2.2 Sales Revenues 425.2.3 ACT 435.2.4 Treatment Usage Patterns 445.2.5 Marketed Products 455.2.6 Drivers and Barriers in the Ovarian Cancer Therapeutics Market 465.3 Multiple Myeloma Therapeutics Market 475.3.1 Introduction 475.3.2 Sales Revenues 495.3.3 ACT 505.3.4 Treatment Usage Patterns 515.3.5 Marketed Products 525.3.6 Drivers and Barriers in the Multiple Myeloma Therapeutics Market 545.4 Acute Myeloid Leukemia Therapeutics Market 555.4.1 Introduction 555.4.2 Sales Revenues 575.4.3 ACT 585.4.4 Treatment Usage Patterns 595.4.5 Marketed Products 605.4.6 Drivers and Barriers in the Acute Myeloid Leukemia Therapeutics Market 615.5 Hodgkin Lymphoma Therapeutics Market 625.5.1 Introduction 625.5.2 Sales Revenues 645.5.3 ACT 655.5.4 Treatment Usage Pattern 665.5.5 Marketed Products 675.5.6 Drivers and Barriers in the Hodgkin Lymphoma Therapeutic Market 686 Orphan Diseases Therapeutics in Oncology - Pipeline Analysis 706.1 Introduction 706.2 R&D Pipeline for Pancreatic Cancer 716.2.1 Phase III 726.2.2 Phase II 726.2.3 Phase I 736.2.4 IND Filed 746.2.5 Preclinical 756.2.6 Discovery 776.2.7 Trends in the Pancreatic Cancer Developmental Pipeline 776.2.8 Promising Pipeline Molecules 786.3 R&D Pipeline for Ovarian Cancer 796.3.1 Phase III 806.3.2 Phase II 816.3.3 Phase I 836.3.4 Preclinical 846.3.5 Discovery 856.3.6 Trends in the Ovarian Cancer Developmental Pipeline 856.3.7 Promising Pipeline Molecules 866.4 R&D Pipeline for Multiple Myeloma 876.4.1 Phase III 886.4.2 Phase II 886.4.3 Phase I 906.4.4 Preclinical 916.4.5 Trends in the Multiple Myeloma Developmental Pipeline 926.4.6 Promising Pipeline Molecules 936.5 R&D Pipeline for Acute Myeloid Leukemia 946.5.1 Phase III 956.5.2 Phase II 956.5.3 Phase I 976.5.4 Preclinical 986.5.5 Discovery 986.5.6 Trends in the Acute Myeloid Leukemia Developmental Pipeline 996.5.7 Promising Pipeline Molecules 1006.6 R&D Pipeline for Hodgkin Lymphoma 1006.6.1 NDA Filed 1016.6.2 Phase III 1016.6.3 Phase II 1016.6.4 Phase I 1026.6.5 Trends in the Hodgkin Lymphoma Developmental Pipeline 1026.6.6 Promising Pipeline Molecules 1037 Orphan Diseases Therapeutics in Oncology Therapeutics Market - Competitive Landscape 1047.1 Celgene Corporation 1047.1.1 SWOT Analysis 1047.2 Genentech, Inc. 1057.2.1 SWOT Analysis 1057.3 Amgen, Inc. 1067.3.1 SWOT Analysis 1067.4 Eli Lilly and Company 1077.4.1 SWOT Analysis 1077.5 Takeda Pharmaceutical Company Ltd. 1087.5.1 SWOT Analysis 1088 Orphan Diseases Therapeutics in Oncology - M&A, Licensing and Co-Development Landscape 1098.1 Overview 1098.2 M&A Landscape 1098.2.1 M&A Deals by Year 1098.2.2 M&A Deals by Geography 1108.2.3 M&A Deals by Value 1118.2.4 M&A Deals by Deal Type 1128.2.5 Major M&A Deals 1128.3 R&D Licensing Agreements 1148.3.1 Deals by Year 1148.3.2 Deals by Geography 1158.3.3 Deals by Value 1168.3.4 Major Licensing Agreements 1178.4 Co-Development Agreements 1198.4.1 Deals by Year 1198.4.2 Deals by Geography 1208.4.3 Deals by Value 1218.4.4 Major Co-Development Agreements 1229 Orphan Diseases Therapeutics in Oncology - Appendix 1239.1 Market Definitions 1239.2 Abbreviations 1239.3 Sources 1249.4 Research Methodology 1249.4.1 Coverage 1249.4.2 Secondary Research 1249.4.3 Primary Research 1259.4.4 Therapeutic Landscape 1259.4.5 Geographical Landscape 1289.4.6 Pipeline Analysis 1289.4.7 Competitive Landscape 1289.4.8 Expert Panel Validation 1289.5 Contact Us 1289.6 Disclaimer 128

1.1 List of Tables

Table 1: Orphan Diseases Therapeutics in Oncology, Global, Revenue ($m), 2004-2010 15Table 2: Orphan Diseases Therapeutics in Oncology, Global, Revenue Forecast ($m), 2010-2018 15Table 3: Orphan Diseases Therapeutics in Oncology, Global, ACT ($), 2004-2010 16Table 4: Orphan Diseases Therapeutics in Oncology, Global, ACT ($), 2010-2018 16Table 5: Orphan Diseases Therapeutics in Oncology, Global, Treatment Usage Pattern, 2004-2010 17Table 6: Orphan Diseases Therapeutics in Oncology, Global, Treatment Usage Pattern, 2010-2018 18Table 7: Orphan Diseases Therapeutics in Oncology, The US, Revenue ($m), 2004-2010 20Table 8: Orphan Diseases Therapeutics in Oncology, The US, Revenue Forecast ($m), 2010-2018 20Table 9: Orphan Diseases Therapeutics in Oncology, The US, ACT ($), 2004-2010 21Table 10: Orphan Diseases Therapeutics in Oncology, The US, ACT ($), 2010-2018 21Table 11: Orphan Diseases Therapeutics in Oncology, The US, Treatment Usage Pattern, 2004-2010 22Table 12: Orphan Diseases Therapeutics in Oncology, The US, Treatment Usage Pattern, 2010-2018 23Table 13: Orphan Diseases Therapeutics in Oncology, Top Five Countries of Europe, Revenue ($m), 2004-2010 24Table 14: Orphan Diseases Therapeutics in Oncology, Top Five Countries of Europe, Revenue Forecasts ($m), 2010-2018 25Table 15: Orphan Diseases Therapeutics in Oncology, Top Five Countries of Europe, ACT ($), 2004-2010 26Table 16: Orphan Diseases Therapeutics in Oncology, Top Five Countries of Europe, ACT ($), 2010-2018 26Table 17: Orphan Diseases Therapeutics in Oncology, Top Five Countries of Europe, Treatment Usage Pattern, 2004-2010 27Table 18: Orphan Diseases Therapeutics in Oncology, Top Five Countries of Europe, Treatment Usage Pattern, 2010-2018 28Table 19: Orphan Diseases Therapeutics in Oncology, Japan, Revenue ($m), 2004-2010 29Table 20: Orphan Diseases Therapeutics in Oncology, Japan, Revenue Forecast ($m), 2010-2018 29Table 21: Orphan Diseases Therapeutics in Oncology, Japan, ACT ($), 2004-2010 30Table 22: Orphan Diseases Therapeutics in Oncology, Japan, ACT ($), 2010-2018 30Table 23: Orphan Diseases Therapeutics in Oncology, Japan, Treatment Usage Pattern, 2004-2010 31Table 24: Orphan Diseases Therapeutics in Oncology, Japan, Treatment Usage Pattern, 2010-2018 32Table 25: Pancreatic Cancer Therapeutics Market, Global, Revenue ($m), 2004-2010 35Table 26: Pancreatic Cancer Therapeutics Market, Global, Revenue Forecast ($m), 2010-2018 35Table 27: Pancreatic Cancer Therapeutics Market, Global, ACT ($), 2004-2010 36Table 28: Pancreatic Cancer Therapeutics Market, Global, ACT ($), 2010-2018 36Table 29: Pancreatic Cancer Therapeutics Market, Global, Treatment Usage Pattern ('000), 2004-2010 37Table 30: Pancreatic Cancer Therapeutics Market, Global, Treatment Usage Pattern ('000), 2010-2018 37Table 31: Ovarian Cancer Therapeutics Market, Global, Revenue ($m), 2004-2010 42Table 32: Ovarian Cancer Therapeutics Market, Global, Revenue Forecast ($m), 2010-2018 42Table 33: Ovarian Cancer Therapeutics Market, Global, ACT ($), 2004-2010 43Table 34: Ovarian Cancer Therapeutics Market, Global, ACT ($), 2010-2018 43Table 35: Ovarian Cancer Therapeutics Market, Global, Treatment Usage Pattern ('000), 2004-2010 44Table 36: Ovarian Cancer Therapeutics Market, Global, Treatment Usage Pattern ('000), 2010-2018 45Table 37: Multiple Myeloma Therapeutics Market, Global, Revenue ($m), 2004-2010 49Table 38: Multiple Myeloma Therapeutics Market, Global, Revenue Forecast ($m), 2010-2018 49Table 39: Multiple Myeloma Therapeutics Market, Global, ACT ($), 2004-2010 50Table 40: Multiple Myeloma Therapeutics Market, Global, ACT ($), 2010-2018 50Table 41: Multiple Myeloma Therapeutics Market, Global, Treatment Usage Pattern ('000), 2004-2010 51Table 42: Multiple Myeloma Therapeutics Market, Global, Treatment Usage Pattern ('000), 2010-2018 52Table 43: Acute Myeloid Leukemia Therapeutics Market, Global, Revenue ($m), 2004-2010 57Table 44: Acute Myeloid Leukemia Therapeutics Market, Global, Revenue Forecast ($m), 2004-2018 57Table 45: Acute Myeloid Leukemia Therapeutics Market, Global, ACT ($), 2004-2010 58Table 46: Acute Myeloid Leukemia Therapeutics Market, Global, ACT ($), 2010-2018 58Table 47: Acute Myeloid Leukemia Therapeutics Market, Global, Treatment Usage Pattern, 2004-2010 59Table 48: Acute Myeloid Leukemia Therapeutics Market, Global, Treatment Usage Pattern ('000), 2010-2018 60Table 49: Hodgkin Lymphoma Therapeutics Market, Global, Revenue ($m), 2004-2010 64Table 50: Hodgkin Lymphoma Therapeutics Market, Global, Revenue Forecast ($m), 2010-2018 64Table 51: Hodgkin Lymphoma Therapeutics Market, Global, ACT ($), 2004-2010 65Table 52: Hodgkin Lymphoma Therapeutics Market, Global, ACT ($), 2010-2018 65Table 53: Hodgkin Lymphoma Therapeutics Market, Global, Treatment Usage Pattern ('000), 2004-2010 66Table 54: Hodgkin Lymphoma Therapeutics Market, Global, Treatment Usage Pattern ('000), 2010-2018 66Table 55: Orphan Diseases Therapeutics in Oncology, Pipeline Analysis, Number of Lead Compounds by Indication, 2011 71Table 56: Pancreatic Cancer Therapeutics Market, Global, Product Pipeline, Phase III, 2011 72Table 57: Pancreatic Cancer Therapeutics Market, Global, Product Pipeline, Phase II, 2011 72Table 58: Pancreatic Cancer Therapeutics Market, Global, Product Pipeline, Phase I, 2011 73Table 59: Pancreatic Cancer Therapeutics Market, Global, Product Pipeline, IND Filed, 2011 74Table 60: Pancreatic Cancer Therapeutics Market, Global, Product Pipeline, Preclinical, 2011 75Table 61: Pancreatic Cancer Therapeutics Market, Global, Product Pipeline, Discovery, 2011 77Table 62: Ovarian Cancer Therapeutics Market, Global, Product Pipeline, Phase III, 2011 80Table 63: Ovarian Cancer Therapeutics Market, Global, Product Pipeline, Phase II, 2011 81Table 64: Ovarian Cancer Therapeutics Market, Global, Product Pipeline, Phase I, 2011 83Table 65: Ovarian Cancer Therapeutics Market, Global, Product Pipeline, Preclinical, 2011 84Table 66: Ovarian Cancer Therapeutics Market, Global, Product Pipeline, Discovery, 2011 85Table 67: Multiple Myeloma Therapeutics Market, Global, Product Pipeline, Phase III, 2011 88Table 68: Multiple Myeloma Therapeutics Market, Global, Product Pipeline, Phase II, 2011 88Table 69: Multiple Myeloma Therapeutics Market, Global, Product Pipeline, Phase I, 2011 90Table 70: Multiple Myeloma Therapeutics Market, Global, Product Pipeline, Preclinical, 2011 91Table 71: Acute Myeloid Leukemia Therapeutics Market, Global, Product Pipeline, Phase III, 2011 95Table 72: Acute Myeloid Leukemia Therapeutics Market, Global, Product Pipeline, Phase II, 2011 95Table 73: Acute Myeloid Leukemia Therapeutics Market, Global, Product Pipeline, Phase I, 2011 97Table 74: Acute Myeloid Leukemia Therapeutics Market, Global, Product Pipeline, Preclinical, 2011 98Table 75: Acute Myeloid Leukemia Therapeutics Market, Global, Product Pipeline, Discovery, 2011 98Table 76: Hodgkin Lymphoma Therapeutics Market, Global, Product Pipeline, NDA Filed, 2011 101Table 77: Hodgkin Lymphoma Therapeutics Market, Global, Product Pipeline, Phase III, 2011 101Table 78: Hodgkin Lymphoma Therapeutics Market, Global, Product Pipeline, Phase II, 2011 101Table 79: Hodgkin Lymphoma Therapeutics Market, Global, Product Pipeline, Phase I, 2011 102

1.2 List of Figures

Figure 1: Orphan Diseases Therapeutics in Oncology, Global, Revenue ($m), 2004-2018 15Figure 2: Orphan Diseases Therapeutics in Oncology, Global, ACT ($), 2004-2018 16Figure 3: Orphan Diseases Therapeutics in Oncology, Global, Treatment Usage Pattern, 2004-2018 17Figure 4: Orphan Diseases Therapeutics in Oncology, The US, Revenue ($m), 2004-2018 20Figure 5: Orphan Diseases Therapeutics in Oncology, The US, ACT ($), 2004-2018 21Figure 6: Orphan Diseases Therapeutics in Oncology, The US, Treatment Usage Pattern, 2004-2018 22Figure 7: Orphan Diseases Therapeutics in Oncology, Top Five Countries of Europe, Revenue ($m), 2004-2018 24Figure 8: Orphan Diseases Therapeutics in Oncology, Top Five Countries of Europe, ACT ($), 2004-2018 26Figure 9: Orphan Diseases Therapeutics in Oncology, Top Five Countries of Europe, Treatment Usage Pattern, 2004-2018 27Figure 10: Orphan Diseases Therapeutics in Oncology, Japan, Revenue ($m), 2004-2018 29Figure 11: Orphan Diseases Therapeutics in Oncology, Japan, ACT ($), 2004-2018 30Figure 12: Orphan Diseases Therapeutics in Oncology, Japan, Treatment Usage Pattern ('000), 2004-2018 31Figure 13: Pancreatic Cancer Therapeutics Market, Global, Revenue ($m), 2004-2018 34Figure 14: Pancreatic Cancer Therapeutics Market, Global, ACT ($), 2004-2018 36Figure 15: Pancreatic Cancer Therapeutics Market, Global, Treatment Usage Pattern ('000), 2004-2018 37Figure 16: Pancreatic Cancer Therapeutics Market, Drivers and Barriers 39Figure 17: Ovarian Cancer Therapeutics Market, Global, Revenue ($m), 2004-2018 42Figure 18: Ovarian Cancer Therapeutics Market, Global, ACT ($), 2004-2018 43Figure 19: Ovarian Cancer Therapeutics Market, Global, Treatment Usage Pattern ('000), 2004-2018 44Figure 20: Ovarian Cancer Therapeutics Market, Drivers and Barriers 46Figure 21: Multiple Myeloma Therapeutics Market, Global, Revenue ($m), 2004-2018 49Figure 22: Multiple Myeloma Therapeutics Market, Global, ACT ($), 2004-2018 50Figure 23: Multiple Myeloma Therapeutics Market, Global, Treatment Usage Pattern ('000), 2004-2018 51Figure 24: Multiple Myeloma Therapeutics Market, Drivers and Barriers 54Figure 25: Acute Myeloid Leukemia Therapeutics Market, Global, Revenue ($m), 2004-2018 57Figure 26: Acute Myeloid Leukemia Therapeutics Market, Global, ACT ($), 2004-2018 58Figure 27: Acute Myeloid Leukemia Therapeutics Market, Global, Treatment Usage Pattern ('000), 2004-2018 59Figure 28: Acute Myeloid Leukemia Therapeutics Market, Drivers and Barriers 61Figure 29: Hodgkin Lymphoma Therapeutics Market, Global, Revenue ($m), 2004-2018 64Figure 30: Hodgkin Lymphoma Therapeutics Market, Global, ACT ($), 2004-2018 65Figure 31: Hodgkin Lymphoma Therapeutics Market, Global, Treatment Usage Pattern ('000), 2004-2018 66Figure 32: Hodgkin Lymphoma Therapeutics Market, Drivers and Barriers 68Figure 33: Pancreatic Cancer Therapeutics Market, Global, R&D Pipeline by Stage of Development, %, 2011 71Figure 34: Pancreatic Cancer Therapeutics Market, Pipeline Molecules by Mechanism of Action, 2011 77Figure 35: Ovarian Cancer Therapeutics Market, Global, R&D Pipeline by Stage of Development, %, 2011 79Figure 36: Ovarian Cancer Therapeutics Market, Pipeline Molecules by Mechanism of Action, 2011 85Figure 37: Multiple Myeloma Therapeutics Market, Global, R&D Pipeline by Stage of Development, %, 2011 87Figure 38: Multiple Myeloma Therapeutics Market, Pipeline Molecules by Mechanism of Action, 2011 92Figure 39: Acute Myeloid Leukemia Therapeutics Market, Global, R&D Pipeline by Stage of Development , %, 2011 94Figure 40: Acute Myeloid Leukemia Therapeutic Market, Pipeline Molecules by Mechanism of Action, 2011 99Figure 41: Hodgkin Lymphoma Therapeutics Market, Global, R&D Pipeline by Stage of Development, %, 2011 100Figure 42: Hodgkin Lymphoma Therapeutic Market, Pipeline Molecules by Mechanism of Action, 2011 102Figure 43: Orphan Diseases Therapeutics in Oncology, Global, SWOT, Celgene Corporation 104Figure 44: Orphan Diseases Therapeutics in Oncology, Global, SWOT, Genentech 105Figure 45: Orphan Diseases Therapeutics in Oncology, Global, SWOT, Amgen 106Figure 46: Orphan Diseases Therapeutics in Oncology, Global, SWOT, Eli Lilly and Company 107Figure 47: Orphan Diseases Therapeutics in Oncology, Global, SWOT, Takeda Pharmaceutical 108Figure 48: Orphan Diseases Therapeutics in Oncology, Global, M&A by Year, 2005-2011 109Figure 49: Orphan Diseases Therapeutics in Oncology, Global, M&A by Geography, 2005-2011 110Figure 50: Orphan Diseases Therapeutics in Oncology, Global, M&A by Value, 2005-2011 111Figure 51: Orphan Diseases Therapeutics in Oncology, Global, M&A by Deal Type, 2005-2011 112Figure 52: Orphan Diseases Therapeutics in Oncology, Global, Licensing Agreements by Year, 2005-2011 114Figure 53: Orphan Diseases Therapeutics in Oncology, Global, Licensing Agreements by Region, 2005-2011 115Figure 54: Orphan Diseases Therapeutics in Oncology, Global, Licensing Agreements by Value, 2005-2011 116Figure 55: Orphan Diseases Therapeutics in Oncology, Global, Co-Development Agreements by Year, 2005-2011 119Figure 56: Orphan Diseases Therapeutics in Oncology, Global, Co-Development Agreements by Region, 2005-2011 120Figure 57: Orphan Diseases Therapeutics in Oncology, Global, Co-Development Agreements by Region, 2005-2011 121Figure 58: GBI Research Market Forecasting Model 127

Companies mentioned

Celgene Corporation

Genentech, Inc.

Amgen, Inc.

Eli Lilly and Company

Takeda Pharmaceutical Company Ltd.

To order this report:Therapy Industry: -Scope-of-Current-Late-Stage-Molecules.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy title='Orphan Diseases Therapeutics in Oncology to 2018 - Strongly Diversified Developmental Pipelines Indicate Long-Term Growth Potential despite Moderate Scope of Current Late Stage Molecules'>Orphan Diseases Therapeutics in Oncology to 2018 - Strongly Diversified Developmental Pipelines Indicate Long-Term Growth Potential despite Moderate Scope of Current Late Stage Molecules

Market Research Report

Check our

Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker